Track record · closed signal

Abbott Laboratories (ABT) — closed signal from July 18, 2025

Near target Published before the outcome was known, scored automatically when the window closed on October 16, 2025 — +3.3% at the close.

Predicted vs. what happened

ABT price · publication thesis → realized outcomesplit-adjusted

$119.93 – $122.90Entry zone — fair-value band

$123.54Published — price the day we called it

$137.75Target — the price the thesis aimed for

$136.88Peak — highest point inside the window, not a realized return

$127.63Window close — end-of-window price, context only

What happened

Near target

Came within reach: 90% of the predicted growth at its peak, just short of the target.

At window close

+3.3%

realized, from the publication price to the last close inside the window

Peak gain

+10.8%

peak, from the publication price — not a realized return

S&P 500, same window

+5.6%

SPY over the identical days, dividend-adjusted

Window close

$127.63

last close inside the window, ended October 16, 2025

Peak price

$136.88

peak on September 22, 2025 — not a realized return

Days to target

—

The thesis — published July 18, 2025

Predicted growth

+12%

over the measurement window

Target price

$137.75

the price the thesis aimed for

Entry zone

$119.93 – $122.90

the fair-value band we waited for

Price at publication

$123.54

published July 18, 2025

Confidence

68%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Abbott’s share price dropped after the company gave a careful outlook even though it earned more than expected. Very few traders are buying now, so the price looks unusually low. Some investors see the fall as temporary because talk of lower interest rates often steers money toward steady healthcare firms. Yet slower product roll-outs and possible rule changes for its glucose monitor could weigh on growth. A climb toward $138 could happen, but certainty is low.

Primary drivers

The price looks beat up yet sentiment is upbeat, a mix that often fuels quick relief rallies.
Talk of lower rates makes safe healthcare stocks more appealing to big investors right now.
Heavy buying showed up even after the drop, signaling traders are ready to step in again.
October earnings preview offers a timed news event that could spark renewed interest.

How it played out

ABT: target was not reached

Lyra published ABT at $123.54 on July 18, 2025. The thesis expected 12% growth toward $137.75. It pointed to a beat-up price, upbeat sentiment, rate-cut talk favoring steady healthcare stocks, heavy buying after the drop, and an October earnings preview as a possible timed catalyst.

Inside the window, ABT rose but stayed below the target. The peak was $136.88 on September 22, a 10.8% gain. It never got there. By October 16, the stock ended at $127.63. The thesis partially played out, but the published target was missed.

What happened during the window

On October 15, 2025, Abbott reported third-quarter sales of $11.37 billion and adjusted earnings of $1.30 per share. The same day, Barron's reported that Abbott narrowed its 2025 adjusted earnings guidance to $5.12 to $5.18.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All ABT signals